Basic characteristics between the LUTS group and the non-LUTS group.

<p>Data are number (%). LUTS =  lower urinary tract symptoms; SD =  standard deviation.</p

Risks of hospitalization for the composite outcome (acute coronary syndrome or stroke) in the LUTS group and the non-LUTS group.

<p>LUTS =  lower urinary tract symptoms; PY =  person-year; IR =  incidence rate, per 1000 person-years; IRR =  incidence rate ratio.</p>*<p>Estimated with Poisson regression.</p

Probabilities of hospitalization for (1a) composite outcome of acute coronary syndrome or stroke, (1b) acute coronary syndrome, (1c) stroke, in subjects with and without lower urinary tract symptoms (LUTS).

<p>Probabilities of hospitalization for (1a) composite outcome of acute coronary syndrome or stroke, (1b) acute coronary syndrome, (1c) stroke, in subjects with and without lower urinary tract symptoms (LUTS).</p

Univariate and multivariable Cox proportional hazards regression analyses for the risk of hospitalization for the composite outcome.

*<p>The model contained all the listed variables.</p><p>LUTS =  lower urinary tract symptom; HR = hazard ratio; CI = confidence interval.</p

Highly Diastereoselective Preparation of Aldol Products Using New Functionalized Allylic Aluminum Reagents

Chloro-substituted triethylsilyl enol ethers derived from cyclo­hexanone and related ketones are converted with aluminum powder in the presence of indium trichloride to functionalized allylic aluminum reagents which represent a new type of synthetic equivalent of metal enolates. These allylic organometallics undergo highly diastereo­selective additions to aldehydes and methyl aryl ketones, giving aldol products with a β-quaternary center

Patient characteristics and association with (n = 447) and without (n = 52802) liver abscess among end-stage renal disease dialysis patients.

<p>Data are n (%) unless otherwise indicated. LA: liver abscess. PD: Peritoneal dialysis; HD: Hemodialysis.</p

Risk factor for long-term mortality after liver abscess in end-stage renal disease dialysis patients (n = 447).

<p>*HR adjusted for sex, age, dialysis modalities, diabetic mellitus, congestive heart failure, coronary artery disease, cerebrovascular accident, chronic obstructive pulmonary disease, polycystic kidney disease, malignancy, chronic liver disease, biliary tract disease and alcoholism.</p><p>*HR: Hazard ratio; CI: Confidence interval; PD: Peritoneal dialysis; HD: Hemodialysis; COPD: chronic obstructive pulmonary disease; PCKD: polycystic kidney disease.</p><p>*<i>P</i><0.05.</p

Risk factor for liver abscess after initiation of dialysis in end-stage renal disease dialysis patients (n = 53,249).

<p>*HR adjusted for sex, age, dialysis modality, diabetic mellitus, polycystic kidney.</p><p>disease, malignancy, chronic liver disease, biliary tract disease and alcoholism.</p><p>*HR: Hazard ratio; CI: Confidence interval; PD: Peritoneal dialysis; HD: Hemodialysis; PCKD: polycystic kidney disease.</p

Cumulative proportion of liver abscess in end-stage renal disease dialysis patients.

<p>Cumulative proportion of liver abscess in end-stage renal disease dialysis patients.</p

Incidence, risk factors, and in-hospital mortality from liver abscess in different study population.

<p>DM: diabetes mellitus; PCKD: polycystic kidney disease.</p